enGene Therapeutics Inc.
ENGNNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $119.25M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.40$12.25
- Volume (live)
- -
- Avg. volume (3M)
- 778.45K
enGene Therapeutics (ENGN) Stock Price & Financial Analysis
enGene Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $1.65 - $1.75 |
|---|---|
| 52-Week High | $12.25 |
| 52-Week Low | $1.40 |
| Open | $1.73 |
| Volume (last close) | 1.16M |
| Average Volume (3M) | 778.45K |
| 50-Day MA | $1.84 |
|---|---|
| 200-Day MA | $4.79 |
| 1-Year Change | −81.71% |
| Market Cap | 119.25M |
|---|---|
| Shares Outstanding | 69.73M |
| Price to Book (P/B) | 0.52 |
| EV/EBITDA | -0.80 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
enGene Therapeutics at a Glance
As of the Oct 16, 2026 close, enGene Therapeutics (ENGN) has a market capitalization of $119.25M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $41.02M in cash and securities against $25.35M of debt, a net cash position of $15.67M.
enGene Therapeutics does not currently pay a dividend.
The share price is down 81.7% over the past year. At $1.67 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $1.40 to $12.25, below its 200-day moving average of $4.79.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $2.50, 50.2% above the Oct 16, 2026 close.
Frequently Asked Questions About enGene Therapeutics
What is the current stock price for ENGN?
As of the Oct 16, 2026 close, ENGN stock trades at $1.67. The 52-week range is $1.40–$12.25, with a day range of $1.65–$1.75.
What is the P/E ratio for ENGN?
The P/E ratio (Price-to-Earnings) for ENGN is shown in the Key Statistics section. This valuation metric helps compare enGene Therapeutics Inc. to industry peers.
Does ENGN pay dividends?
enGene Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ENGN?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for ENGN is Hold. The average 12-month price target is $2.50, a 50.2% upside from the Oct 16, 2026 close of $1.67.
What is the market cap of ENGN?
As of the Oct 16, 2026 close, enGene Therapeutics's market capitalization is $116.1M, classifying it as a micro-cap company. enGene Therapeutics operates in the Healthcare sector within the Biotechnology industry.